Carlsmed Q2 revenue $18.9M (+57% YoY); raises FY2026 guidance to $74-78M

CARLSMED, INC.

Revenue $18.9M, up 57% YoY from $12.1M; gross margin 76.8% vs 73.4%.
Net loss ($10.5M) vs ($6.8M) prior year; adjusted EBITDA ($8.6M).
Full-year 2026 revenue guidance raised to $74-78M (prior $72-77M), >50% growth at midpoint.
Trained surgeon users up >60% YoY; aprevo cervical now ~10% of quarterly revenue.
CMS IPPS final rule includes new MS-DRG codes for inpatient aprevo lumbar, effective Oct 1, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.